Skip to main content

Table 3 Relationship between SLFN11 expression level and clinicopathological variables

From: The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

Variable SLFN-11 expression P value
Low High
n (%) n (%)
Gender Male 32 (52.5) 29 (47.5) 0.345
Female 4 (33.3) 8 (66.7)
Age < 65 9 (34.6) 17 (65.4) 0.062
≥ 65 27 (57.4) 20 (42.6)
Number of pre-dCRT biopsy specimens including tumor tissue 1 5 (45.5) 6 (54.5) 0.781
≥ 2 31 (50.0) 31 (50.0)
Histological type Differentiated 33 (51.6) 31 (48.4) 0.725
Un-differentiated 3 (33.3) 6 (66.7)
Depth of invasion cT1b or T2 12 (50.0) 12 (50.0) 0.935
cT3 - T4b 24 (49.0) 25 (51.0)
Tumor size < 5 cm 17 (48.6) 18 (51.4) 0.903
≥ 5 cm 19 (50.0) 19 (50.0)
Lymphatic metastasis cN0 11 (45.8) 13 (54.2) 0.677
(regional lymph node) cN1 - N3 25 (51.0) 24 (49.0)
Distant metastasis cM0 32 (50.8) 31 (49.2) 0.736
(distant lymph node) cM1 -lym 4 (40.0) 6 (60.0)
  1. Abbreviations: CI confidence interval, cT1b tumor invasion to the submucosa, cT2 tumor invasion to the muscularis propria, cT3 tumor invasion to the adventitia, cT4b tumor invades adjacent structures, such as the aorta, vertebral body, or trachea, cN0 no regional lymph node metastasis, cN1 metastasis in 1–2 regional lymph nodes, cN3 metastasis in 7 or more regional lymph nodes, cM0 no distant metastasis, cM1-lym distant lymph node metastasis, dCRT definitive chemoradiotherapy